Asthma with multiple allergic comorbidities is associated with complete response to omalizumab

Abstract

Patients with severe asthma constitute a heterogeneous population, and different phenotypes have been identified both in adults and children. Severe asthma affects 4.5% of children with current asthma. Several studies have shown that omalizumab, a humanized anti‐IgE monoclonal antibody, is effective in exacerbations and asthma control, and well tolerated in children with severe allergic asthma^. However, as biotherapy response varies among patients, it is important to clearly define which children will benefit the most from treatment.

This article is protected by copyright. All rights reserved.

http://bit.ly/2trpgo1